These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 20466670)

  • 21. Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study.
    Molina P; Molina MD; Pallardó LM; Torralba J; Escudero V; Álvarez L; Peris A; Sánchez-Pérez P; González-Rico M; Puchades MJ; Fernández-Nájera JE; Giménez-Civera E; D'Marco L; Carrero JJ; Górriz JL
    J Nephrol; 2021 Aug; 34(4):1189-1199. PubMed ID: 33394344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysis from the MBD-5D study.
    Asada S; Yokoyama K; Miyakoshi C; Fukuma S; Endo Y; Wada M; Nomura T; Onishi Y; Fukagawa M; Fukuhara S; Akizawa T
    Clin Exp Nephrol; 2020 Jul; 24(7):630-637. PubMed ID: 32236781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study.
    Melamed ML; Eustace JA; Plantinga L; Jaar BG; Fink NE; Coresh J; Klag MJ; Powe NR
    Kidney Int; 2006 Jul; 70(2):351-7. PubMed ID: 16738536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients.
    Zhou X; Guo Y; Luo Y
    Ren Fail; 2021 Dec; 43(1):599-605. PubMed ID: 33781171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients.
    Barrera-Baena P; Rodríguez-García M; Rodríguez-Rubio E; González-Llorente L; Ortiz A; Zoccali C; Locatelli F; Floege J; Cohen-Solal M; Ferreira MA; Ketteler M; London GM; Gorriz-Teruel JL; Sánchez-Álvarez E; Hevia-Suárez MÁ; Fernández-Gómez JM; Martín-Carro B; Gómez-Alonso C; Alonso-Montes C; Cannata-Andía JB; Fernández-Martín JL;
    Nephrol Dial Transplant; 2024 Mar; 39(4):618-626. PubMed ID: 37660283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients.
    Noordzij M; Boeschoten EW; Bos WJ; Dekker FW; Bossuyt PM; Krediet RT; Korevaar JC;
    Nephrol Dial Transplant; 2007 Oct; 22(10):2944-9. PubMed ID: 17597087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.
    Goldberg DI; Dillon MA; Slatopolsky EA; Garrett B; Gray JR; Marbury T; Weinberg M; Wombolt D; Burke SK
    Nephrol Dial Transplant; 1998 Sep; 13(9):2303-10. PubMed ID: 9761513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium, phosphorus, cardiovascular events and all-cause mortality in hemodialysis patients: a single-center retrospective cohort study to reassess the validity of the Japanese Society for Dialysis Therapy guidelines.
    Komaba H; Igaki N; Takashima M; Goto S; Yokota K; Komada H; Takemoto T; Kohno M; Kadoguchi H; Hirosue Y; Goto T
    Ther Apher Dial; 2008 Feb; 12(1):42-8. PubMed ID: 18257811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets?
    Fouque D; Roth H; Pelletier S; London GM; Hannedouche T; Jean G; Bouchet JL; Drüeke T
    Nephrol Dial Transplant; 2013 Feb; 28(2):360-7. PubMed ID: 23136211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
    Kumar N; Lindberg J; David K; Morris J; Menoyo J
    Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.
    Palmer SC; Hayen A; Macaskill P; Pellegrini F; Craig JC; Elder GJ; Strippoli GF
    JAMA; 2011 Mar; 305(11):1119-27. PubMed ID: 21406649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.
    Block GA; Kilpatrick RD; Lowe KA; Wang W; Danese MD
    Clin J Am Soc Nephrol; 2013 Dec; 8(12):2132-40. PubMed ID: 24052218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis.
    Chen L; He JX; Chen YY; Ling YS; Lin CH; Guan TJ
    Ren Fail; 2018 Nov; 40(1):15-21. PubMed ID: 29295646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function.
    Bleskestad IH; Bergrem H; Leivestad T; Hartmann A; Gøransson LG
    Clin Transplant; 2014 Apr; 28(4):479-86. PubMed ID: 25649861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study.
    Fernández-Martín JL; Dusso A; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Górriz JL; Rutkowski B; Bos WJ; Tielemans C; Martin PY; Wüthrich RP; Pavlovic D; Benedik M; Rodríguez-Puyol D; Carrero JJ; Zoccali C; Cannata-Andía JB;
    Nephrol Dial Transplant; 2019 Apr; 34(4):673-681. PubMed ID: 29741651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemical markers of mineral bone disorder in South African patients on maintenance haemodialysis.
    Waziri B; Duarte R; Naicker S
    Afr Health Sci; 2017 Jun; 17(2):445-452. PubMed ID: 29062340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorus control in peritoneal dialysis patients.
    Yavuz A; Ersoy FF; Passadakis PS; Tam P; Evaggelos DM; Katopodis KP; Ozener C; Akçiçek F; Camsari T; Ateş K; Ataman R; Vlachojannis GJ; Dombros NA; Utaş C; Akpolat T; Bozfakioğlu S; Wu G; Karayaylali I; Arinsoy T; Stathakis CP; Yavuz M; Tsakiris DJ; Dimitriades AC; Yilmaz ME; Gültekin M; Süleymanlar G; Oreopoulos DG
    Kidney Int Suppl; 2008 Apr; (108):S152-8. PubMed ID: 18379539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.